SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

HEMP BioSciences Inc., a wholly owned division of WEED Inc., will oversee our genetics programs. Panama Red, Acapulco Gold, Red Bud Colombian and Santa Marta Gold top the list.

TUCSON, AZ / ACCESS CABLE / July 20, 2022 / WEED, Inc. (OTCQB:BUDZ) (“WEED” or the “Company”), a US-based global cannabis and hemp bio-research company focused on the development and application of cannabis-derived compounds for the treatment of human and animal diseases. announced today that it has acquired 100% of Hempirical Genetics, LLC, for 2 million shares of common stock. Values valued at $.25 per share and $250,000 in cash over 4 years. At the signing of this contract, one million shares and $10,000.00 were paid. The Company sees the acquisition as a game changer, one that will help secure WEED’s growth and dedication to new discoveries in the field of medical cannabis. WEED researchers will now have a plethora of options to discover the TRUE benefits of the Cannabaceae plant.


Sponsored Content:


Glenn E. Martin, CEO of WEED, Inc., states, “Our teams in the US, Australia and Israel are excited that a line of original ‘Landrace’ strains from the 1970s can now be moved into trials.” clinical and product development for the world market WEED now has over 15 original, pristine, “PURE” F-1 grade cannabis strains including Panama Red, Acapulco Gold, Red Bud Colombian and Santa Marta Gold. recently acquired includes over 30 CBD and CBG strains, as WEED believes multiple combinations of precise cannabinoid strains will create the entourage. effect to achieve the desired medical result. WEED eventually plans to bring our unique desired strains to adult use markets once the ‘Law of the Earth’ restores the freedoms lost over 70 years ago.”

Mr. Jeffery Miller, the previous owner of Hempirical Genetics, will lead strain and product development as the new CEO of HEMP BioScience. Mr. Martin comments, “I’ve known Jeff for half a century. His horticultural skills and his dedication to the Canabacae plant cannot be duplicated. I am extremely proud to have my old friend and his team (whose strains WEED purchased in the acquisition), who we believe will bring success year after year to the benefit of WEED shareholders.”

Mr. Jeffery Miller comments: “I have known Glenn Martin for over 50 years and it is an honor to take the helm of HEMP BioSciences to develop our genetic studies. My goal is to bring the strongest, highest quality THC and hemp products to market at affordable prices. “Double the quality, half the price” should be the mantra of the cannabis industry, while creating Diversity and Equality in the cannabis sector. Our veterans have been sorely overlooked, and I am looking to develop low-cost or NO-cost veterans programs, which I know is a priority for Glenn and me.”

“WEED seeks to reinstate its R&D in clinical trials nationally, as well as in Israel, together with sister company, WEED Israel Cannabis Ltd. in product development and educational tools for physicians, healthcare professionals and the public. Jeff will be the key coordinator for our studies globally.” Says Glenn E. Martin: “Our primary goal now is to develop a portfolio of highly effective products, both pharmaceutical and non-pharmaceutical, to further the understanding and uses of cannabis and its derived forms, from high-THC compounds to high-THC compounds. CBD and CBG. Research is key to long-term success. An informed client is your best patient.” Martin continues; “We believe that most of the discoveries in cannabis and hemp have yet to be found. These are exciting times! Jeffery Miller and WEED seek to shift the global health mindset toward natural remedies.”


Sponsored Content: OurLifeStore.com is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping


Caution Regarding Cannabis Operations in the United States

Investors should be aware that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. While legal in certain states, cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis. Financial transactions involving income generated from, or with the intent to further, commercial cannabis-related activities in the United States may form the basis for prosecution under applicable United States federal money laundering laws. Investors should carefully read the risk factors and disclosures contained in our offering circulate before making any decision to invest in our company.

forward-looking information

This press release contains “forward-looking information” within the meaning of applicable securities laws. The forward-looking information contained in this Press release can be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “ forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include statements regarding future income and profits. Forward-looking information is not a guarantee of future performance and is based on a number of management’s estimates and assumptions in light of management’s experience and perception of trends, current conditions and expected developments, as well as other relevant factors in the circumstances, including assumptions regarding current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, forward-looking information should not be unduly relied upon because the Company cannot guarantee that they will prove to be correct. Actual results and developments may differ materially from those contemplated in these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. The statements in this Press release are made as of the date of this communication. The Company disclaims any intention or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws.

Legal warning

The information is provided for convenience only, is not investment advice, and should not be relied upon when considering an investment in WEED, Inc. No representation or warranty, express or implied, is made as to the accuracy or completeness of the information. any information contained in this document. and any investment decision should be based solely on the information contained in the offering circular and related materials, and independent research of investors. No representation or warranty, express or implied, is made as to the future performance of any investment in WEED, Inc. or that investors will achieve or are likely to achieve favorable results, obtain any profit or avoid incurring a loss on their investment. investment. In addition, prospective investors are encouraged to consult with their financial, tax, accounting or other advisors to determine if an investment in WEED, Inc. is right for them.

Media Contact:
Glenn E. Martin, CEO
1-520-818-8582
[email protected]

FONT: GRASS, Inc.

See source version at access cable.com:
https://www.accesswire.com/709193/WEED-Inc-USA-Acquires-Hempirical-Genetics-LLC-wOver-250-Proprietary-Cannabis-Hemp-Strains-for-75000000

Source link

Leave a Reply

Your email address will not be published.